MintHealth

minthealth.io

MintHealth enables companies to achieve intended health and economic outcomes with their existing products/services through a universal user rewards and redemption marketplace.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

news image

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

news image

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

news image

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

CELL AND GENE THERAPY

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More
news image

MEDICAL

ABC OPENS COMMERCIAL MEL BIOSURFACTANT PRODUCTION IN IRVINE, CA

ABC | May 19, 2022

Advanced BioCatalytics (ABC) is pleased to announce the opening of our new biosurfactant commercial pilot plant in Irvine California. The plant reflects the successful collaboration of the ABC R&D team and Dr. Wenjie Xia, professor of Microbiology at Nankai University in Tianjin China. The commercial pilot plant is the first step in commercial scale up of new glycolipid (biosurfactants) and is the first plant to produce commercial quantities of mannosylerythritol lipids (MEL) in North Americ...

Read More
news image

INDUSTRIAL IMPACT

RIBBON BIOLABS ESTABLISHES IP PORTFOLIO WITH FIRST GRANTED U.S. PATENT COVERING FAST, COST-EFFECTIVE, LONG DNA SYNTHESIS TECHNOLOGY

Ribbon Biolabs | July 20, 2022

Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 2020283756 A1, covering Ribbon Biolabs’ novel method for synthesizing a double stranded polynucleotide, also known as DNA, using a diverse library of oligonucleotides. The patent is the first of its submitted patent applications to be granted to the company, forming the foundation of its IP portfolio covering its long DNA synthesis technology. “ Read More

news image

CELL AND GENE THERAPY

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More